We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Allogeneic hematopoietic stem cell transplantation in patients with therapy‐related hematologic malignancies developing after multiple myeloma.
- Authors
Vasudevan Nampoothiri, Ram; Pasic, Ivan; Law, Arjun Datt; Lam, Wilson; Chen, Carol; Michelis, Fotios V.; Kim, Dennis; Gerbitz, Armin; Lipton, Jeffrey Howard; Kumar, Rajat; Mattsson, Jonas; Viswabandya, Auro
- Abstract
Introduction: Increasing survival of patients with multiple myeloma (MM) has resulted in an increased recognition of therapy‐related hematological malignancies (t‐MDS/AML, t‐ALL, and t‐CMML). There are limited data on the role of allogeneic hematopoietic stem cell transplantation (HCT) in this patient population. Patients and Methods: We retrospectively reviewed patients who underwent HCT for t‐MDS/AML, t‐ALL, and t‐CMML developing after receiving treatment for MM at our center. Patients were analyzed for myeloma characteristics and therapy, time to diagnosis of therapy‐related hematological neoplasms, clinical, laboratory characteristics, transplant details, relapse‐free survival (RFS), and overall survival (OS). Results: Twenty patients underwent HCT for therapy‐related hematological malignancies after MM (t‐MDS/AML = 13, t‐ALL = 6, t‐CMML = 1). Median(range) age at time of transplant was 62.5 (49–73) years and 70% (n = 14) were male. The most common cytogenetic abnormality was complex/monosomal karyotype in 30% (n = 6) followed by monosomy/deletion of chromosome 5 or 7 in 15% (n = 3) of patients each. Donors were human leukocyte antigen matched (10/10 or 6/6) siblings in 30% (n = 6), unrelated in 60% (n = 12) and haploidentical in 10% (n = 2) patients. Estimated 2‐year OS and RFS for the whole cohort were 53.1% and 47.2% respectively. There was a trend toward better survival in patients with t‐ALL when compared to t‐MDS/AML; however, the difference was not statistically significant. We did not find any pre‐transplant or post‐transplant factors that were predictive of survival outcomes after multivariate analysis. Conclusions: Allogeneic HCT provides substantial long‐term disease‐free survival in a proportion of patients with MM‐associated therapy‐related hematological malignancies. Multicenter studies with more patients and longer follow‐up may provide additional information about factors affecting outcomes.
- Subjects
HEMATOPOIETIC stem cell transplantation; MULTIPLE myeloma; HEMATOLOGIC malignancies; HLA histocompatibility antigens; MONOCLONAL gammopathies; PLASMA cell diseases
- Publication
European Journal of Haematology, 2022, Vol 108, Issue 5, p430
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/ejh.13750